News

BStartup, Banco Sabadell’s service for startups and scaleups, has launched the 5^th Edition of BStartup Health, with the aim of continuing to support young innovative companies engaging in the health sector, as well as guaranteeing their future viability.

This new edition has already open its registration process during the entire month of September throughout Spain, after which a total of three projects will be selected following the structure of its previous editions. Each of these projects will receive an investment of up to €150,000, which is linked to specific criteria: it must be a Spanish company with international reach and growth prospects, with a differential and innovative value proposition, led by entrepreneurs and engaging in the fields of medical devices, diagnostics, therapeutics and drugs or e-health. Furthermore, the project must be at pre-seed, seed or early-stage and aim to reach maturity with optimal and desirable guarantees for subsequent investment rounds with sector venture capital.

In addition, the startups selected will benefit from a support plan through which they will receive mentorship from one of the four members of BStartup Health’s scientific-technical committee, made up by expert health investors with ample entrepreneurial and/or scientific experience. This committee is comprised of Dr Clara Campàs, co-founder of Asabys Partners; Carlos Gallardo, Chairman of the Board of Directors of Almiral and founder of CG Health Partners; Dr Damià Tormo, founder and general partner at Columbus Venture Partners; and Dr Montserrat Vendrell, partner at Alta Life Sciences. A significant part of this process will focus on specialist business advice at the strategic level, the definition of a road map or guidance in terms of the fundraising strategy, etc. In addition, the companies selected will have access to some of the most relevant investors and will receive support from the BStartup team during activities such as the preparation for an investment round.

Yolanda Pérez, BStartup Director, says: “Since its first edition, BStartup Health has focused on investment in these very early stages, which are key for the research-company transfer to take place and for these projects to carry out the necessary validations to go to market and be ready for subsequent investment rounds. We are very satisfied with the trajectory that the 12 startups that have received investment in previous editions are currently enjoying”.

The registration process for the 5^th Edition of BStartup Health is open until 2 October on the BStartup official website.

About BStartup Health

The BStartup Health programme was born in 2018 and is aimed at health projects in very early stages, in which the investment is mainly allocated to validate the technology and the market and in which there is precisely less available investment.

During the four previous editions, 511 projects were submitted and the following companies were selected: Time is Brain, Thytech, Sycai Medical, Inbrain Neuroelectronics, Gate2Brain, Dive Medical, Admit Therapeutics, Able Human Motion, Renalyse, Oxolife, Doppli and MiWEndo, which engage in fields as diverse as Alzheimer’s, treatment of strokes, mobility solutions for people with disabilities, kidney disease diagnosis, early cancer detection or human reproduction.

Banco Sabadell’s commitment

Banco Sabadell Group continues to strengthen its position as a prominent agent in the health sector covering various investment stages as main investor of Sabadell Asabys Health Innovation Fund which carries out investment in early stages in the areas of biotech, medtech, digital health and innovative services, as well as benchmark investor in Ysios Biofund II Innvierte.

Furthermore, since 2006 the Banco Sabadell Foundation gives out the Biomedical Research Award, in order to recognise young researchers with an outstanding track-record in the field of biomedical and health sciences research, who stand out in their speciality for their capacity for innovation.